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Background: Heme arginate can induce heme oxygenase-1 to protect tissue against ischemia-reperfusion injury.
Blood oxygen level dependent (BOLD) functional magnetic resonance imaging measures changes in tissue
oxygenation with a high spatial and temporal resolution. BOLD imaging was applied to test the effect of heme
arginate on experimental ischemia reperfusion injury in the calf muscles.
Methods: A two period, controlled, observer blinded, crossover trial was performed in 12 healthy male subjects.
Heme arginate (1 mg/kg body weight) or placebo were infused 24 h prior to a 20 min leg ischemia induced by a
thigh cuff. 3 Tesla BOLD-imaging of the calf was performed and signal time courses from soleus, gastrocnemius
and tibialis anterior muscle were available from 11 participants for technical reasons.
Results: Peak reactive hyperemia signal of the musculature was significantly increased and occurred earlier after
heme arginate compared to placebo (106.2±0.6% at 175±16s vs. 104.5±0.6% at 221±19s; p = 0.025 for peak
reperfusion and p = 0.012 for time to peak).
Conclusions: A single high dose of heme arginate improves reperfusion patterns during ischemia reperfusion
injury in humans. BOLD sensitive, functional MRI is applicable for the assessment of experimental ischemia




Rapid reperfusion is essential for ischemic muscle. How-
ever, reperfusion itself can result in additional damage to
ischemic tissue [1,2]. One of the key mechanisms is the
rise of free oxygen radicals, thereby exceeding the cellu-
lar antioxidant capacity and damaging cellular proteins
and membranes [3]. In a second step, neutrophil activa-
tion and tissue invasion is part of the deleterious cascade
of ischemia-reperfusion injury (IRI) [4].
Several strategies to alleviate IRI have been tested
in various experimental settings, including mechanical
preconditioning and postconditioning, pharmacologic* Correspondence: michael.wolzt@meduniwien.ac.at
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reproduction in any medium, provided the orpreconditioning, administration of antioxidant substances
and treatment with endothelin receptor antagonists [5-10].
As a new therapeutic approach in humans, the induc-
tion of the enzyme heme oxygenase 1 (HO-1) may be
employed to mitigate IRI [10,11]. HO-1 is the rate-
limiting enzyme for the degradation of heme b [12].
Thereby, it produces biliverdin, carbon monoxide (CO)
and iron. Recently, the role of HO-1 as a protective
enzyme was proposed due to its anti-inflammatory,
antioxidant, anti-apoptotic and antiproliferative actions
[11,13]. HO-1 is expressed in several organs including
endothelial and smooth muscle cells in response to cellu-
lar stress conditions [14-16].
IRI may be attenuated by pharmacological HO-1
induction with heme arginate (HA) as shown in a rodent
hemorrhagic shock model [11,17-19]. Previous data haveLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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and protein by HA in venous blood of healthy subjects
[20,21].
In this therapeutic exploratory study, we aimed to
evaluate the effects of HA on skeletal muscle IRI in
healthy humans. Blood oxygen level dependent (BOLD)
functional magnetic resonance imaging (fMRI) was used
to measure alterations in tissue oxygenation with a high
spatial and temporal resolution [22,23]. fMRI has previ-
ously been used to assess perfusion of the calf muscles
in elderly people and patients with peripheral arterial oc-
clusive disease after ischemia reperfusion experiments
[24-26]. Further, we could measure an effect of ischemic
preconditioning in healthy subjects on BOLD fMRI peak
signal during reperfusion [27].
Methods
A two period placebo controlled, observer blinded, ran-
domized crossover trial was performed in 12 healthy
male subjects between 18 and 46 years (age [mean ±
standard deviation] 28±6 years, body mass index 22.6
±2.1 kg/m2). Functional MRI signals could not be ana-
lysed in one participant for technical reasons. There-
fore, data are shown for 11 subjects. The study
protocol was approved by the Ethics Committee of the
Medical University of Vienna. All participants gave
written informed consent prior to inclusion. One
screening visit and two study periods with a washout
time of at least 10 days in-between were scheduled for
each participant. Physical examination and medical his-
tory, routine blood works including blood count,a)
Figure 1 Experimental setup. a) EPI images for every 4th minute during t
parameters derived from fitted curves. Caption: Time course is showed in m
arbitrary units; min: minutes.clinical chemistry, urine analysis and a 12-lead electro-
cardiogram were performed at the screening visit one
week prior to the first study day. Subjects did not take
any medication throughout the study and abstained
from alcohol, stimulating beverages containing xanthine
derivatives (tea, coffee) and heavy physical exercise 48
hours before drug infusion and fMRI. Subjects were
fasted on study days. After the last treatment a final
follow-up examination was performed.
A single dose of 1 mg/kg heme arginate or placebo
(sodium chloride) was administered as an intravenous
infusion in the alternate study periods. Heme arginate
was diluted to 110 ml with 0.9% NaCl. The infusion was
administered within 15 minutes at an infusion rate of
440 ml/h using an infusomat (IP 85–2, Döring, Munich,
Germany). A post-treatment infusion of 250 ml 0.9%
NaCl was administered to rinse perfusion lines.
Each study period consisted of three days. On the first
day, placebo or heme arginate were administered. On
the second day, the fMRI and ischemia reperfusion
protocol was performed. On the third day, a blood draw
for analysis of creatine kinase, lactate dehydrogenase,
total protein, blood iron and C – reactive proteine as
well as a physical examination were done.
Ischemia was administered to the right lower leg for
20 minutes using a cuff inflated to 200 mmHg on the
thigh (Figure 1b). The cuff was deflated to 30 mmHg
below systolic pressure for five minutes for slow reperfu-
sion, mimicking impaired blood perfusion through the
femoral artery. This setting has been validated previously
[27]. A blood draw for NO2/NO3 analysis was performedb) fMRI timeline
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he experiment; b) fMRI timeline, a sample data set and description of
inutes; 1: peak BOLD signal; 2: time to peak; 3: tangent slope; a.u.:




Systolic blood pressure pre ischemia (mmHg) 115±10 114±8
Diastolic blood pressure pre ischemia (mmHg) 80±8 77±8
Heart rate pre ischemia (bpm) 73±4 72±4
Systolic blood pressure post ischemia (mmHg) 116±10 115±9
Diastolic blood pressure post ischemia (mmHg) 81±7 80±10
Heart rate post ischemia (bpm) 71±2 70±3
Blood iron (μg/dl) 110±41 100±38
Protein (g/l) 76.0±3.8 75.9±2.3
Lactate dehydrogenase (U/l) 152±28 154±28
Creatine kinase (U/l) 148±114 146±87
C – reactive protein (mg/dl) 0.06±0.05 0.08±0.09
Data are presented as mean±SD, n = 12.
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15 minutes after ischemia.
MR operators were blinded to the randomization se-
quence. A Siemens Tim Trio (Siemens Medical Solu-
tions, Erlangen, Germany) was used for scanning.
Anatomical images were acquired at the beginning of
the MR examination. BOLD-imaging (EPI) had the fol-
lowing parameters: 128 x 128 matrix, twenty 5 mm axial
slices, 1,42 mm in-plane resolution, TR = 2 s, TE = 28 ms.
1700 EPI stacks were acquired every TR. Imaging started
two minutes before ischemia and continued for at least
25 minutes after reperfusion (Figure 1a + b). Regions of
interest (ROI) were drawn around the soleus, gastrocne-
mius and tibialis anterior muscle for signal analysis. The
BOLD signals in the ROIs as well as from all voxels were
summed to achieve a single time course for each individ-
ual muscle and the complete calf respectively. The start-
ing point of reperfusion was determined manually in all
individual data sets.
To describe the BOLD response in calf muscle during
reperfusion, the intensity time courses were fitted
against a similar function as is used in DCE first pass
perfusion measurements using Matlab (Mathworks,
Natick, MA, USA) using the Curve Fitting Toolbox
(Schewzow et al., submitted):
f tð Þ ¼ g tð Þ þ s tð Þ þ l tð Þ ð1Þ
is the sum of gamma variate function g(t)
g tð Þ ¼ g0  t  t0ð Þgl  eg2 tt0ð Þ ð2Þ
and a sigmoid function s(t)
s tð Þ ¼ s0  1
1þ esI tt0tIð Þ
ð3Þ
A linear function l(t) was also added to take into ac-
count a possible drift of the signal during the experiment
l tð Þ ¼ l0 þ ll t  t0ð Þ ð4Þ
The values of peak BOLD signal, time to peak and tan-
gent slope were determined numerically from the fitted
curves f(t) (Figure 1b).
The effect of heme arginate infusion on nitric oxide
synthase was measured by NO2 and NO3 plasma con-
centration prior to heme arginate administration as well
as prior to and 15 minutes after ischemia as previously
described [28].
Descriptive statistics were used for outcome and safety
parameters. To detect a treatment effect in a continuous
outcome parameter of one standard deviation by a
paired t-test with a two-sided significance level of 5%, 12
subjects had to be recruited to achieve a power of ap-
proximately 90%. With a maximum of two subjectsdropping out (16.7%), power is still at 80%. The fitted
measures time to peak, peak BOLD signal and slope of
reperfusion signal decline of each muscle of interest
were analyzed as dependent variables using a general lin-
ear mixed model, including the fixed factors ‘treatment
day’ (placebo or administration of heme arginate) and
muscle (soleus, gastrocnemius and tibialis anterior), and
the random factor ‘subject’. An interaction of treatment
day and muscle was evaluated and dropped from the
model if not significant. Pairwise post-hoc comparisons
between muscles were corrected for multiple testing using
the Fisher’s least significant difference procedure. A two-
sided p-value lower than 0.05 was considered indicating
statistical significance. PASW 18.0 (SPSS Inc., Chicago,
Illinois, USA) was used for statistical computations.
Results
HA was tolerated well without adverse reaction. No sig-
nificant difference of vital signs or safety blood para-
meters could be detected between study periods
(Table 1). An increased creatine kinase serum concentra-
tion of up to 490 U/l occurred 24 hours after ischemia
in two different subjects (one receiving HA, one receiv-
ing placebo) but resolved spontaneously.
Heme arginate administration 24 hours prior to ische-
mia increased peak BOLD reperfusion signal from 104.5
±0.6% to 106.2±0.6% compared to placebo (Figure 2d;
p = 0.025). Furthermore, the time to peak reperfusion
was reduced from 221±19 seconds to 175±16 seconds
versus placebo (p = 0.012). The calculated slope of reper-
fusion signal decline after peak was significantly steeper
after heme arginate compared to control condition
(−2.8*10-4±0.2*10-4 vs. -2.1*10-4±0.2*10-4; p = 0.002).
There was no significant effect of heme arginate on the
BOLD signal during ischemia.






































































































Figure 2 BOLD signal during reperfusion – group average showing treatment effect. a) gastrocnemius muscle; b) soleus muscle; c) tibialis
anterior muscle; d) all three muscles. Caption: Reperfusion signal was fitted according to the described protocol; a.u.: arbitrary units, normalized to
the pre-ischemic signal; min: minutes.
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depicted in Figure 2a-c and summarized in Table 2. Peak
reperfusion signal after placebo was highest in the soleus
muscle and lowest in the gastrocnemius muscle (106.5Table 2 BOLD signal of calf muscles after ischemia-
reperfusion injury
All muscles TTP (s) PEAK (%) slope (1/s)
placebo 221±19 104.5±0.6 −2.1*10-4±0.2*10-4
HA 175±16 106.2±0.6 −2.8*10-4±0.2*10-4
p-value 0.012 0.025 0.002
gastrocnemius
placebo 250±36 102.6±0.8 −1.6*10-4±0.2*10-4
HA 198±11 104.0±0.6 −2.2*10-4±0.2*10-4
soleus
Placebo 244±31 106.5±0.7 −2.6*10-4±0.4*10-4
HA 182±8 107.8±0.8 −3.2*10-4±0.4*10-4
Tibialis ant.
Placebo 169±28 104.3±1.2 −2.0*10-4±0.3*10-4
HA 152±13 106.9±1.5 −3.0*10-4±0.4*10-4
Heme arginate or placebo were administered 24 hours prior to ischemia. Data
are mean±SD, n = 11; p-value was calculated using a general linear mixed
model and applies to all comparisons, since interaction analysis suggested
homogeneity of the treatment effect across muscles. TTP: time to peak; PEAK:
peak reperfusion signal; slope: slope of the tangent at the inflection point of
the BOLD signal curve after the peak; HA: heme arginate.±0.7% vs. 102.6±0.8%, p = 0.019). A similar reaction
across calf muscles to heme arginate could be confirmed
by statistical analysis.
Plasma concentrations of NO2 and NO3 were 2.7
±1.4 μmol/l and 13.1±8.3 μmol/l 24 hours after heme
arginate administration compared to 3.5±1.8 μmol/l and
12.4±8.3 μmol/l after placebo, respectively (p = not sig-
nificant). Plasma concentrations of NO2 and NO3 before
heme arginate administration and after ischemia were
also unchanged.
Discussion
This study demonstrates beneficial effects of HA pre-
treatment on endothelial function and reperfusion pat-
terns after IRI in healthy humans. Full reperfusion signal
occurred earlier, was higher and declined faster com-
pared to placebo. We have previously reported that
BOLD fMRI is able to characterize reperfusion patterns
and the protective effects of ischemic preconditioning in
IRI experiments [27]. Furthermore, we have shown the
ability of HA to induce heme oxygenase-1 mRNA and
protein in humans [21]. The induction of HO-1 proved
beneficial in several ischemia reperfusion models in ani-
mal studies [11,17,19]. However, the application of HA
against IRI in humans has not been reported yet.
We propose a stronger and earlier peak BOLD signal
during reperfusion as the healthy response. This
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decreased BOLD fMRI signal in elderly subjects [25,26].
Furthermore, subjects with overt peripheral artery occlu-
sive disease presented with decreased and delayed peak
BOLD signal during reperfusion [24]. HA increased the
peak reperfusion signal by 38% compared to the increase
over baseline after placebo administration. This is in line
with one report showing a 44% higher peak signal in
healthy subjects compared to the BOLD signal increase
during reperfusion in elderly subjects [26]. We could
furthermore demonstrate a faster decline of the reactive
hyperemia signal after the peak in the HA period, indi-
cated by a steeper decline of the slope in the infliction
point of the reperfusion signal curve.
The BOLD fMRI signal is determined by a combined
influence of perfusion, vascular microarchitecture and
oxygen saturation of hemoglobin and myoglobin. Unfor-
tunately, the individual contributions of each of these
factors to the finally observed signal cannot be sepa-
rated. Regions of interest were drawn around muscles to
exclude confounding signal influences from main ves-
sels, fatty tissue and bones. The soleus muscle, a slow-
twitch fibre muscle, is known to show a high capillary
density [29]. It showed the highest peak reperfusion
value, as also reported in previous trials [26,27]. Vaso-
dilation of muscular capillaries may therefore be a strong
contributor to the BOLD signal. Since this trial had a
crossover design and results were analysed with a
repeated measurement model, an influence of vessel
architecture to the different peak signals is unlikely.
Improved perfusion may therefore be the major con-
tributor to the peak BOLD signal. However, muscular
metabolism may also influence oxygen extraction and
hemoglobin saturation during reperfusion [27]. There-
fore, the BOLD signal cannot be directly compared to
reperfusion patterns measured by flow-mediated dilation
or strain gauge plethysmography [30]. It seems plausible
that a protected endothelial cell function is responsible
for faster and increased maximal reperfusion, leading
also to more rapid and increased oxygen saturation in
the muscles under study. The faster normalization of the
reperfusion signal after peak may be an additional sign
of protected endothelial cell function and adequate early
reperfusion of muscular tissue. This protection may be
mediated by decreased heme toxicity and increased anti-
oxidative capacity due to HO-1 induction and the action
of its enzymatic products biliverdin/bilirubin and carbon
monoxide [11]. Ischemia leads to a stasis of red blood
cells in the ischemic tissue. Red blood cells are subject-
ive to reactive oxygen radicals which are increasingly
produced during ischemia and early reperfusion [31,32].
A limitation of this trial is the short period of ische-
mia. An increased ischemic period may reveal greater
tissue injury and alter the protective effects of HAadministration but is not feasible due to ethical con-
cerns. Further, we have not measured HO-1 mRNA and
protein levels in this trial. Clinical studies in patients
with acute ischemic events are mandatory to validate
these experiments accordingly. To draw more general
conclusions, a female group and subjects with different
underlying diseases should be included in future studies.
Arginine, the substrate of nitric oxide synthase, may
exert systemic vasodilator effects mediated by nitric
oxide [33]. To analyse a possible contribution of
increased nitric oxide synthase activity induced by heme
arginate, NO2 and NO3 levels were measured in plasma.
The lack of changes in systemic nitric oxide metabolites
argues against major vascular nitric oxide stimulation as
a confounder of our results.
Our interpretation has to be discussed with caution in
the context of previously published results. We reported
an increased phosphocreatine overshoot and a decreased
peak BOLD signal after ischemic preconditioning four
hours prior to 20 minutes of ischemia. The phospho-
creatine overshoot indicated an improved mitochondrial
function by ischemic preconditioning, which may ex-
plain the increased oxygen demand leading to a
decreased peak BOLD signal after ischemic precondi-
tioning. Therefore, we suggest that the protecting effects
of HA are different from the effects of ischemic precon-
ditioning. The induction of HO-1 seems to be down-
stream in the cascade of ischemic preconditioning
[34,35]. Therefore, different patterns in fMRI time series
of these two protecting interventions as demonstrated
by fMRI so far are reasonable. Furthermore, the fMRI
measurement parameters were not identical in all stud-
ies. We increased the number of slices and decreased
the slice gap for reduced artefacts from through-plane
motion at the cost of reduced temporal resolution and
shorter echo time. This enabled better signal-to-noise
ratio but showed a slightly different contrast. Therefore,
a direct, numerical comparison with our previous study
is not possible [27].Conclusions
In conclusion, application of heme arginate improves
reperfusion patterns during IRI and may protect endo-
thelial cells and skeletal muscle against IRI in humans.
The potential clinical applications of this intervention
have to be addressed in further trials.
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